[18F]Tetrafluoroborate, a new NIS PET/CT radiopharmaceutical: an overview focused on differentiated thyroid cancer
Background: In relapsing differentiated thyroid cancer (DTC), the in vivo evaluation of natrium–iodide symporter (NIS) expression is pivotal in the therapeutic planning and is achieved by 131/123Iodine (131/123I) whole body scan. However, these approaches have low sensitivity due to the low resoluti...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2025-02-01
|
| Series: | European Thyroid Journal |
| Subjects: | |
| Online Access: | https://etj.bioscientifica.com/view/journals/etj/14/1/ETJ-24-0320.xml |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823863573815754752 |
|---|---|
| author | Arnoldo Piccardo Francesco Fiz Sergio Righi Stefano Raffa Mattia Riondato Gianluca Bottoni Matteo Bauckneht Michela Massollo Alessio Rizzo Mehrdad Shoushtari Zadeh Naseri Pierpaolo Trimboli Giorgio Treglia |
| author_facet | Arnoldo Piccardo Francesco Fiz Sergio Righi Stefano Raffa Mattia Riondato Gianluca Bottoni Matteo Bauckneht Michela Massollo Alessio Rizzo Mehrdad Shoushtari Zadeh Naseri Pierpaolo Trimboli Giorgio Treglia |
| author_sort | Arnoldo Piccardo |
| collection | DOAJ |
| description | Background: In relapsing differentiated thyroid cancer (DTC), the in vivo evaluation of natrium–iodide symporter (NIS) expression is pivotal in the therapeutic planning and is achieved by 131/123Iodine (131/123I) whole body scan. However, these approaches have low sensitivity due to the low resolution of SPECT. 18F-Tetrafluoroborate (TFB) has been proposed as a viable alternative, which could outperform 131/123I scans owing to the superior PET resolution. We have reviewed the literature to collect the available data on TFB diagnostic performance and compare it with the standard methods. Methods: Two authors searched PubMed, CENTRAL, Scopus, Web of Science and the web for studies evaluating the biodistribution and dosimetry of TFB in patients with DTC. General characteristics, technical parameters, procedures’ sensitivities and standards of reference were extracted from the selected studies. The risk of bias was evaluated with the QUADAS-2 scoring system. Results: Five studies were included in the review. Two analysed TFB’s biodistribution and dosimetry, while the other three assessed its diagnostic performance. The diagnostic comparators were 18F-FDG PET/CT (all cases), 124I-PET/CT (one study) and diagnostic/therapeutic 131I-SPECT/CT (one study each). TFB performed better than 131I; the TFB and 18F-FDG PET/CT combination achieved the best sensitivity. TFB delivered significantly less dose than the other NIS tracers. Conclusion: TFB is a promising tracer in relapsing DTC, showing higher sensitivity and less radiation exposure than the standard methods. The TFB and 18F-FDG combination appears particularly intriguing, especially when disease heterogeneity is suspected. However, data are still sparse and need to be confirmed by further investigations. |
| format | Article |
| id | doaj-art-068184a5fd9c47dcbefe06f465b5498c |
| institution | Kabale University |
| issn | 2235-0802 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | European Thyroid Journal |
| spelling | doaj-art-068184a5fd9c47dcbefe06f465b5498c2025-02-09T12:04:56ZengBioscientificaEuropean Thyroid Journal2235-08022025-02-0114110.1530/ETJ-24-03201[18F]Tetrafluoroborate, a new NIS PET/CT radiopharmaceutical: an overview focused on differentiated thyroid cancerArnoldo Piccardo0Francesco Fiz1Sergio Righi2Stefano Raffa3Mattia Riondato4Gianluca Bottoni5Matteo Bauckneht6Michela Massollo7Alessio Rizzo8Mehrdad Shoushtari Zadeh Naseri9Pierpaolo Trimboli10Giorgio Treglia11S.C. di Medicina Nucleare, Galliera Hospital, Genoa, ItalyS.C. di Medicina Nucleare, Galliera Hospital, Genoa, ItalyS.S.D. Fisica Medica, Galliera Hospital, Genoa, ItalyDepartment of Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genova, ItalyDepartment of Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genova, ItalyS.C. di Medicina Nucleare, Galliera Hospital, Genoa, ItalyDepartment of Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genova, ItalyS.C. di Medicina Nucleare, Galliera Hospital, Genoa, ItalyDepartment of Nuclear Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, ItalyS.C. di Medicina Nucleare, Galliera Hospital, Genoa, ItalyFaculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, SwitzerlandFaculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, SwitzerlandBackground: In relapsing differentiated thyroid cancer (DTC), the in vivo evaluation of natrium–iodide symporter (NIS) expression is pivotal in the therapeutic planning and is achieved by 131/123Iodine (131/123I) whole body scan. However, these approaches have low sensitivity due to the low resolution of SPECT. 18F-Tetrafluoroborate (TFB) has been proposed as a viable alternative, which could outperform 131/123I scans owing to the superior PET resolution. We have reviewed the literature to collect the available data on TFB diagnostic performance and compare it with the standard methods. Methods: Two authors searched PubMed, CENTRAL, Scopus, Web of Science and the web for studies evaluating the biodistribution and dosimetry of TFB in patients with DTC. General characteristics, technical parameters, procedures’ sensitivities and standards of reference were extracted from the selected studies. The risk of bias was evaluated with the QUADAS-2 scoring system. Results: Five studies were included in the review. Two analysed TFB’s biodistribution and dosimetry, while the other three assessed its diagnostic performance. The diagnostic comparators were 18F-FDG PET/CT (all cases), 124I-PET/CT (one study) and diagnostic/therapeutic 131I-SPECT/CT (one study each). TFB performed better than 131I; the TFB and 18F-FDG PET/CT combination achieved the best sensitivity. TFB delivered significantly less dose than the other NIS tracers. Conclusion: TFB is a promising tracer in relapsing DTC, showing higher sensitivity and less radiation exposure than the standard methods. The TFB and 18F-FDG combination appears particularly intriguing, especially when disease heterogeneity is suspected. However, data are still sparse and need to be confirmed by further investigations.https://etj.bioscientifica.com/view/journals/etj/14/1/ETJ-24-0320.xmltetrafluoroborateiodinenatrium–iodine symporterdifferentiated thyroid cancer |
| spellingShingle | Arnoldo Piccardo Francesco Fiz Sergio Righi Stefano Raffa Mattia Riondato Gianluca Bottoni Matteo Bauckneht Michela Massollo Alessio Rizzo Mehrdad Shoushtari Zadeh Naseri Pierpaolo Trimboli Giorgio Treglia [18F]Tetrafluoroborate, a new NIS PET/CT radiopharmaceutical: an overview focused on differentiated thyroid cancer European Thyroid Journal tetrafluoroborate iodine natrium–iodine symporter differentiated thyroid cancer |
| title | [18F]Tetrafluoroborate, a new NIS PET/CT radiopharmaceutical: an overview focused on differentiated thyroid cancer |
| title_full | [18F]Tetrafluoroborate, a new NIS PET/CT radiopharmaceutical: an overview focused on differentiated thyroid cancer |
| title_fullStr | [18F]Tetrafluoroborate, a new NIS PET/CT radiopharmaceutical: an overview focused on differentiated thyroid cancer |
| title_full_unstemmed | [18F]Tetrafluoroborate, a new NIS PET/CT radiopharmaceutical: an overview focused on differentiated thyroid cancer |
| title_short | [18F]Tetrafluoroborate, a new NIS PET/CT radiopharmaceutical: an overview focused on differentiated thyroid cancer |
| title_sort | 18f tetrafluoroborate a new nis pet ct radiopharmaceutical an overview focused on differentiated thyroid cancer |
| topic | tetrafluoroborate iodine natrium–iodine symporter differentiated thyroid cancer |
| url | https://etj.bioscientifica.com/view/journals/etj/14/1/ETJ-24-0320.xml |
| work_keys_str_mv | AT arnoldopiccardo 18ftetrafluoroborateanewnispetctradiopharmaceuticalanoverviewfocusedondifferentiatedthyroidcancer AT francescofiz 18ftetrafluoroborateanewnispetctradiopharmaceuticalanoverviewfocusedondifferentiatedthyroidcancer AT sergiorighi 18ftetrafluoroborateanewnispetctradiopharmaceuticalanoverviewfocusedondifferentiatedthyroidcancer AT stefanoraffa 18ftetrafluoroborateanewnispetctradiopharmaceuticalanoverviewfocusedondifferentiatedthyroidcancer AT mattiariondato 18ftetrafluoroborateanewnispetctradiopharmaceuticalanoverviewfocusedondifferentiatedthyroidcancer AT gianlucabottoni 18ftetrafluoroborateanewnispetctradiopharmaceuticalanoverviewfocusedondifferentiatedthyroidcancer AT matteobauckneht 18ftetrafluoroborateanewnispetctradiopharmaceuticalanoverviewfocusedondifferentiatedthyroidcancer AT michelamassollo 18ftetrafluoroborateanewnispetctradiopharmaceuticalanoverviewfocusedondifferentiatedthyroidcancer AT alessiorizzo 18ftetrafluoroborateanewnispetctradiopharmaceuticalanoverviewfocusedondifferentiatedthyroidcancer AT mehrdadshoushtarizadehnaseri 18ftetrafluoroborateanewnispetctradiopharmaceuticalanoverviewfocusedondifferentiatedthyroidcancer AT pierpaolotrimboli 18ftetrafluoroborateanewnispetctradiopharmaceuticalanoverviewfocusedondifferentiatedthyroidcancer AT giorgiotreglia 18ftetrafluoroborateanewnispetctradiopharmaceuticalanoverviewfocusedondifferentiatedthyroidcancer |